Results - Financial Results for the quarter ended June 30, 2026

August 13, 2026 Listing Department, Listing Department, National Stock Exchange of India Limited BSE Limited Exchange Plaza, Plot C-1, Block G, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai - 400 051 Mumbai - 400 001 Symbol: MAXHEALTH Scrip Code: 543220 Sub.: Outcome of Board Meeting Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, In continuation to our earlier intimation dated August 8, 2026, we wish to inform that the board of directors (“Board”) of the Company at their meeting held today i.e. August 13, 2026, inter-alia, transacted following businesses: Financial Results Approved the unaudited standalone & consolidated financial results (“Financial Results”) of the Company for the quarter ended June 30, 2026, based on the recommendation of Audit Committee. Financial Results together with unmodified limited review reports issued by M/s. S.R. Batliboi & Co. LLP, Chartered Accountants, Statutory Auditors of the Company are enclosed as Annexure - I. Change in Senior Management Personnel Appointment of Senior Management Personnel Approved the appointment of Mr. Ajay Vij as Director - Chief Supply Chain & Procurement Officer and Mr. Pawan Kumar Marella as Senior Director - Chief Experience & Brand Officer, identified as Senior Management Personnel, with effect from August 14, 2026 and August 17, 2026 respectively, based on the recommendation of Nomination and Remuneration Committee. Resignation of Senior Management Personnel Dr. N. Venkatesan, Senior Director & Chief Procurement Officer has tendered his resignation and will cease to be a Senior Management Personnel of the Company with effect from the closing hours on August 31, 2026. Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) are enclosed as Annexure – II. Capital Expenditure for expansion of Max Super Speciality Hospital, Vaishali Approved capital expenditure of ~₹425 Crore towards the construction of an additional hospital block viz. ‘Tower 3’ on the ~1-acre land parcel contiguous to the existing hospital as part of the expansion plan of Max Super Speciality Hospital, Vaishali (“MSSH Vaishali”). MSSH Vaishali is run and operated by Crosslay Remedies Limited, a wholly-owned subsidiary of the Company. Details as required under the SEBI Listing Regulations are enclosed as Annexure - III. In-principle approval for setting up of medical colleges/ medical institutions and amendment in Memorandum of Association of the Company Accorded its in-principle approval to explore and evaluate setting up of medical colleges/ medical institutions under the Company or through subsidiary, in view of the proposed amendment to regulations by the National Medical Commission (NMC), allowing any company incorporated under the Companies Act, 2013 to pursue such activity. Further, the Board approved the amendment in the main object clause of the Memorandum of Association of the Company, by incorporating certain additional enabling objects in line with the Company's long-term business strategy and evolving business requirements, subject to the approval of members of the Company. The Board meeting commenced at 11.48 am (IST) and concluded at 2.19 pm (IST). This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above S.R. BATLIBo: & Co. LLP 67, Institutional Area Sector 44, Gurugram - 122 003 Chartered Accountants Haryana, India Tel: +91 124 681 6000 Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Max Healthcare Institute Limited 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Max Healthcare Institute Limited (the "Holding Company"), its subsidiaries and its deemed separate entities, that is 'Silos' over which the Holding Company has control (the Holding Company, its subsidiaries and its deemed separate entities that is 'Silos", together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (md AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the Circular No. CIRICFD/CMDl/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the following entities as mentioned in Annexure I. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of three subsidiaries, whose unaudited interim financial results include total revenues of Rs. 1,881 Laths, total net profit after tax of Rs. 61 Laths, total comprehensive income of Rs. 63 Lakhs, for the quarter ended June 30, 2026 on that date, as considered in the Statement which have been reviewed by their respective independent auditors. S.. BtUboi & C LLP, Lirit1 LiabUt Prtr,erhip with LLP Identity No. AAB-4294 22Cc Siroct BloC: B Cd Floor. Koltcara-10} Ill S.R. IJATLIBOI& Ca LLP Chartered Accountants The indepen [Showing first 8,000 characters — download PDF for full document]